Efficacy in CB 1 receptor-mediated signal transduction

British Journal of Pharmacology

Volumn 142, Issue 8, 2004, Pages 1209-1218

  Howlett, Allyn C ^a,b  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Aminoalkylindoles; Anandamide; Ca 2+ channels; CB 1 receptor ( ) transgenic mice; Cerebellar membranes; CP55940; Cyclic AMP; G protein coupled receptors; GTP S binding; Levonantradol; Radioligand binding assays

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ADENYLATE CYCLASE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; DEXANABINOL; G PROTEIN COUPLED RECEPTOR; LEVONANTRADOL; METHANANDAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN DERIVATIVE; RIMONABANT; CANNABINOID;

BINDING AFFINITY; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; CROSS COUPLING REACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; LIGAND BINDING; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; HUMAN; PHYSIOLOGY;

ANIMALS; CANNABINOIDS; HUMANS; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION;

EID: 4444348830     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705881     Document Type: Review

References (73)

1. ABADJI, V., LUCAS-LENARD, J.M., CHIN, C. & KENDALL, D.A. (1999). Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs. J. Neurochem., 72, 2032-2038.
2. ADAMS, I.B., COMPTON, D.R. & MARTIN, B.R. (1998). Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther., 284, 1209-1217.
3. BASKFIELD, C.Y., MARTIN, B.R. & WILEY, J.L. (2004). Differential effects of delta-9-tetrahydrocannabinol and methanandamide on operant behavior in CB1 knockout and wild type mice. J. Pharmacol. Exp. Ther., 309, 86-91.
4. BONHAUS, D.W., CHANG, L.K., KWAN, J. & MARTIN, G.R. (1998). Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther., 287, 884-888.
5. BOUABOULA, M., PERRACHON, S., MILLIGAN, L., CANAT, X., RINALDI-CARMONA, M., PORTIER, M., BARTH, F., CALANDRA, B., PECCEU, F., LUPKER, J., MAFFRAND, J.P., LE FUR, G. & CASELLAS, P. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem., 272, 22330-22339.
6. BREIVOGEL, C.S. & CHILDERS, S.R. (2000). Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J. Pharmacol. Exp. Ther., 295, 328-336.
7. BREIVOGEL, C.S., GRIFFIN, G., DI, M. & MARTIN, B.R. (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol., 60, 155-163.
8. 35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J. Biol. Chem., 273, 16865-16873.
9. BREIVOGEL, C.S., SIM, L.J. & CHILDERS, S.R. (1997). Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J. Pharmacol. Exp. Ther., 282, 1632-1642.
10. BURKEY, T.H., QUOCK, R.M., CONSROE, P., EHLERT, F.J., HOSOHATA, Y., ROESKE, W.R. & YAMAMURA, H.I. (1997). Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. Eur. J. Pharmacol., 336, 295-298.
11. CHILDERS, S.R., SEXTON, T. & ROY, M.B. (1994). Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem. Pharmacol., 47, 711-715.
12. COMPTON, D.R., GOLD, L.H., WARD, S.J., BALSTER, R.L. & MARTIN, B.R. (1992). Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther., 263, 1118-1126.
13. COMPTON, D.R., RICE, K.C., DE COSTA, B.R., RAZDAN, R.K., MELVIN, L.S., JOHNSON, M.R. & MARTIN, B.R. (1993). Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J. Pharmacol. Exp. Ther., 265, 218-226.
14. DEVANE, W.A., DYSARZ III, F.A., JOHNSON, M.R., MELVIN, L.S. & HOWLETT, A.C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol., 34, 605-613.
15. DIMARZO, V., BREIVOGEL, C.S., TAO, Q., BRIDGEN, D.T., RAZDAN, R.K., ZIMMER, A.M., ZIMMER, A. & MARTIN, B.R. (2000). Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem., 75, 2434-2444.
16. FELDER, C.C., JOYCE, K.E., BRILEY, E.M., GLASS, M., MACKIE, K.P., FAHEY, K.J., CULLINAN, G.J., HUNDEN, D.C., JOHNSON, D.W., CHANEY, M.O., KOPPEL, G.A. & BROWNSTEIN, M. (1998). LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther., 284, 291-297.
17. FELDER, C.C., JOYCE, K.E., BRILEY, E.M., MANSOURI, J., MACKIE, K., BLOND, O., LAI, Y., MA, A.L. & MITCHELL, R.L. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol., 48, 443-450.
18. FELDER, C.C., VELUZ, J.S., WILLIAMS, H.L., BRILEY, E.M. & MATSUDA, L.A. (1992). Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol. Pharmacol., 42, 838-845.
19. GLASS, M. & FELDER, C.C. (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci., 17, 5327-5333.
20. GLASS, M. & NORTHUP, J.K. (1999). Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol. Pharmacol., 56, 1362-1369.
21. GOMEZ, D.P., VELASCO, G. & GUZMAN, M. (2000). The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem. J., 347, 369-373.
22. 35S]thio)-triphosphate binding assay in rat cerebellar membranes. J. Pharmacol. Exp. Ther., 285, 553-560.
23. HILLARD, C.J., HARRIS, R.A. & BLOOM, A.S. (1985). Effects of the cannabinoids on physical properties of brain membranes and phospholipid vesicles: fluorescence studies. J. Pharmacol. Exp. Ther., 232, 579-588.
24. HILLARD, C.J., POUNDS, J.J., BOYER, D.R. & BLOOM, A.S. (1990). Studies of the role of membrane lipid order in the effects of delta 9-tetrahydrocannabinol on adenylate cyclase activation in heart. J. Pharmacol. Exp. Ther., 252, 1075-1082.
25. HOUSTON, D.B. & HOWLETT, A.C. (1998). Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists. Cell Signal., 10, 667-674.
26. HOWLETT, A.C. (2002). The cannabinoid receptors. Prostaglandins Other Lipid Mediat., 68-69, 619-631.
27. HOWLETT, A.C., BARTH, F., BONNER, T.I., CABRAL, G., CASELLAS, P., DEVANE, W.A., FELDER, C.C., HERKENHAM, M., MACKIE, K., MARTIN, B.R., MECHOULAM, R. & PERTWEE, R.G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161-202.
28. HOWLETT, A.C., CHAMPION, T.M., WILKEN, G.H. & MECHOULAM, R. (1990). Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology, 29, 161-165.
29. HOWLETT, A.C., SCOTT, D.K. & WILKEN, G.H. (1989). Regulation of adenylate cyclase by cannabinoid drugs. Insights based on thermodynamic studies. Biochem. Pharmacol., 38, 3297-3304.
30. JARRAHIAN, A., WATTS, V.J. & BARKER, E.L. (2004). D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J. Pharmacol. Exp. Ther., 308, 880-886.
31. KEARN, C.S., GREENBERG, M.J., DICAMELLI, R., KURZAWA, K. & HILLARD, C.J. (1999). Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J. Neurochem., 72, 2379-2387.
32. KENAKIN, T. (1997). Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol. Sci., 18, 456-464.
33. LANDSMAN, R.S., BURKEY, T.H., CONSROE, P., ROESKE, W.R. & YAMAMURA, H.I. (1997). SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol., 334, R1-R2.
34. LEFF, P. (1995). The two-state model of receptor activation. Trends Pharmacol. Sci., 16, 89-97.
35. MACKIE, K. & HILLE, B. (1992). Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. U.S.A., 89, 3825-3829.
36. MACKIE, K., DEVANE, W.A. & HILLE, B. (1993). Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol., 44, 498-503.
37. MACKIE, K., LAI, Y., WESTENBROEK, R. & MITCHELL, R. (1995). Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci., 15, 6552-6561.
38. MACLENNAN, S.J., REYNEN, P.M., KWAN, J. & BONHAUS, D.W. (1998). Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br. J. Pharmacol., 124, 619-622.
39. MAKRIYANNIS, A. & RAPAKA, R.S. (1990). The molecular basis of cannabinoid activity. Life Sci., 47, 2173-2184.
40. MANEUF, Y.P. & BROTCHIE, J.M. (1997). Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br. J. Pharmacol., 120, 1397-1398.
41. MELVIN, L.S., MILNE, G.M., JOHNSON, M.R., SUBRAMANIAM, B., WILKEN, G.H. & HOWLETT, A.C. (1993). Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol. Pharmacol., 44, 1008-1015.
42. MELVIN, L.S., MILNE, G.M., JOHNSON, M.R., WILKEN, G.H. & HOWLETT, A.C. (1995). Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity. Drug Des. Discov., 13, 155-166.
43. MESCHLER, J.P., KRAICHELY, D.M., WILKEN, G.H. & HOWLETT, A.C. (2000). Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chloropnenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. Biochem. Pharmacol., 60, 1315-1323.
44. MUKHOPADHYAY, S. & HOWLETT, A.C. (2000). Chemically distinct agonists promotes differential cannabinoid receptor-G protein dissociation. Pharmacologist.
45. MUKHOPADHYAY, S., MCINTOSH, H.H., HOUSTON, D.B. & HOWLETT, A.C. (2000). The CB(1) cannabinoid receptor juxta-membrane C-terminal peptide confers activation to specific G proteins in brain. Mol. Pharmacol., 57, 162-170.
46. MUKHOPADHYAY, S., SHIM, J.Y., ASSI, A.A., NORFORD, D. & HOWLETT, A.C. (2002). CB(1) cannabinoid receptor-G protein association: a possible mechanism for differential signaling. Chem. Phys. Lipids, 121, 91-109.
47. NAH, S.Y., SAYA, D. & VOGEL, Z. (1993). Cannabinoids inhibit agonist-stimulated formation of inositol phosphates in rat hippocampal cultures. Eur. J. Pharmacol., 246, 19-24.
48. 2+ signals in cerebellar granule neurons in culture. J. Neurosci., 19, 8765-8777.
49. PACHECO, M.A., WARD, S.J. & CHILDERS, S.R. (1994). Differential requirements of sodium for coupling of cannabinoid receptors to adenylyl cyclase in rat brain membranes. J. Neurochem., 62, 1773-1782.
50. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol. Pharmacol., 54, 1064-1072.
51. PERTWEE, R.G. (1999). Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem., 6, 635-664.
52. PETITET, F., JEANTAUD, B., CAPET, M. & DOBLE, A. (1997). Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study. Biochem. Pharmacol., 54, 1267-1270.
53. PRATHER, P.L., MARTIN, N.A., BREIVOGEL, C.S. & CHILDERS, S.R. (2000). Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. Mol. Pharmacol., 57, 1000-1010.
54. RHEE, M.H., BAYEWITCH, M., AVIDOR-REISS, T., LEVY, R. & VOGEL, Z. (1998). Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J. Neurochem., 71, 1525-1534.
55. 3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci., 58, 1239-1247.
56. SANCHEZ, C., GALVE-ROPERH, I., RUEDA, D. & GUZMAN, M. (1998). Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol. Pharmacol., 54, 834-843.
57. SANCHEZ, C., RUEDA, D., SEGUI, B., GALVE-ROPERH, I., LEVADE, T. & GUZMAN, M. (2001). The CB(1) cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein fan. Mol. Pharmacol., 59, 955-959.
58. SELLEY, D.E., RORRER, W.K., BREIVOGEL, C.S., ZIMMER, A.M., ZIMMER, A., MARTIN, B.R. & SIM-SELLEY, L.J. (2001). Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation. J. Neurochem., 77, 1048-1057.
59. 35S]thio)-triphosphate binding in rat brain membranes. Life Sci., 59, 659-668.
60. SHEN, M., PISER, T.M., SEYBOLD, V.S. & THAYER, S.A. (1996). Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci., 16, 4322-4334.
61. SHIM, J.Y., COLLANTES, E.R., WELSH, W.J., SUBRAMANIAM, B., HOWLETT, A.C., EISSENSTAT, M.A. & WARD, S.J. (1998). Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis. J. Med. Chem., 41, 4521-4532.
62. SIM, L.J., SELLEY, D.E., XIAO, R. & CHILDERS, S.R. (1996). Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum. Eur. J. Pharmacol., 307, 97-105.
63. SIM-SELLEY, L.J., BRUNK, L.K. & SELLEY, D.E. (2001). Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur. J. Pharmacol., 414, 135-143.
64. STARK, S., PACHECO, M.A. & CHILDERS, S.R. (1997). Binding of aminoalkylindoles to noncannabinoid binding sites in NG108-15 cells. Cell Mol. Neurobiol., 17, 483-493.
65. 2+ transient in NG108-15 cells. J. Biochem.(Tokyo), 122, 890-895.
66. 2+ in neuroblastoma x glioma hybrid NG108-15 cells. Biochem. Biophys. Res. Commun., 229, 58-64.
67. SUGIURA, T., KODAKA, T., KONDO, S., TONEGAWA, T., NAKANE, S., KISHIMOTO, S., YAMASHITA, A. & WAKU, K. (1997b). Inhibition by 2-arachidonoylglycerol, a novel type of possible neuromodulator, of the depolarization-induced increase in intracellular free calcium in neuroblastoma x glioma hybrid NG108-15 cells. Biochem. Biophys. Res. Commun., 233, 207-210.
68. THOMAS, B.F., COMPTON, D.R. & MARTIN, B.R. (1990). Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J. Pharmacol. Exp. Ther., 255, 624-630.
69. TWITCHELL, W., BROWN, S. & MACKIE, K. (1997). Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol., 78, 43-50.
70. ULFERS, A.L., MCMURRY, J.L., MILLER, A., WANG, L., KENDALL, D.A. & MIERKE, D.F. (2002). Cannabinoid receptor-G protein interactions: G(alphai1)-bound structures of IC3 and a mutant with altered G protein specificity. Protein Sci., 11, 2526-2531.
71. VASQUEZ, C. & LEWIS, D.L. (1999). The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J. Neurosci., 19, 9271-9280.
72. WAELBROECK, I. (1999). Kinetics versus equilibrium: the importance of GTP in GPCR activation. Trends Pharmacol. Sci., 20, 477-481.
73. WARTMANN, M., CAMPBELL, D., SUBRAMANIAN, A., BURSTEIN, S.H. & DAVIS, R.J. (1995). The MAP kinase signal transaction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett., 359, 133-136.